UK Government Allocates £1 billion to Combat Malaria, Other Infectious Diseases

The Sabin Vaccine Institute (Sabin) and its UK sister organization Sabin Foundation Europe, released the following statement on the UK government’s allocation of £1 billion for malaria and other infectious diseases. This funding will be distributed through the newly-developed Ross Fund, created by the Department for International Development (DFID) in collaboration with the Bill and Melinda Gates Foundation.

Sabin PDP, King Saud University Sign Project Agreement to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — November 16, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today signed a project agreement with King Saud University to build vaccine research and development capacity in the Middle East and North Africa (MENA) region and advance the establishment of a vaccine research institute in Saudi Arabia.

Regional Dengue Symposium Addresses Today’s Challenges in Dengue Control

RIO DE JANEIRO, BRAZIL — November 3, 2015 — More than one hundred public health experts and stakeholders gathered today in Rio de Janeiro, Brazil, for the First Regional Dengue Symposium, led by the Pan American Health Organization (PAHO), the Sabin Vaccine Institute (Sabin) and the Dengue Vaccine Initiative (DVI).

New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.

New Global Initiative to Advance Onchocerciasis Vaccine Development for Africa

WASHINGTON, D.C. – August 11, 2015 – The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has joined The Onchocerciasis Vaccine for Africa (TOVA) Initiative, which was established this year to develop and test a vaccine for onchocerciasis. Also known as river blindness, onchocerciasis infects an estimated 17 million people, with more than 99 percent of these cases spread throughout 31 countries in sub-Saharan Africa. Approximately 169 million people are at risk of contracting this disease.

Pages